AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board (CAB).
– Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalities
– Includes immunotherapies and small molecule drugs targeting intracellular proteinopathies
– Leadership in groundbreaking early-stage clinical trials reinforces Company’s competencies